You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Dow
McKinsey
Merck
Medtronic

Last Updated: February 17, 2020

DrugPatentWatch Database Preview

Patent: 9,314,154

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,314,154
Title:System and method for providing analysis of visual function using a mobile device with display
Abstract: A visual function evaluation is performed using a sequence of interactions with a mobile device. A patient user may perform a variety of visual tests using the mobile device. The mobile device transmits the test results to a remote server implementing analysis of the visual function results using network service. The network service receives the test results, processes the results, and provides the processed results to a healthcare provider. The processed results may include trends of the user\'s visual function test performance. The healthcare provider, such as a physician, may optimize and administer treatment based on the data. Early detection of changes in visual function can enable the healthcare provider to individualize treatment, helping to prevent vision loss while minimizing visits to the office, discomfort, and expense.
Inventor(s): Palanker; Daniel (Palo Alto, CA), Blumenkranz; Mark (Los Altos Hills, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Application Number:14/352,571
Patent Claims:see list of patent claims

Details for Patent 9,314,154

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA) 2031-10-17 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA) 2031-10-17 RX Orphan search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA) 2031-10-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,314,154

Country Patent Number Publication Date
United States of America 2014285769 Sep 25, 2014
United States of America 2015201832 Jul 23, 2015
United States of America 2016213243 Jul 28, 2016
United States of America 2016374551 Dec 29, 2016
United States of America 2017143202 May 25, 2017
United States of America 9462941 Oct 11, 2016
United States of America 9572484 Feb 21, 2017
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Dow
Johnson and Johnson
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.